Clever Culture secures $2.6m to build smaller APAS system
Clever Culture raised $2.6 million to build APAS Revolution, a smaller device for drug makers to check quality.
Clever Culture (ASX:CC5) raised $1 million through share sales and $1.6 million through a loan. The funds will develop APAS Revolution.
The device lets smaller drug makers check quality without needing the full power of the current model. Major pharma firms including Pfizer, AstraZeneca and CSL already use APAS Independence.
The new system could grow the total market from $2.8 billion to $4.3 billion. Test units should be ready by late 2027.
Full launch is aimed for the first half of 2028.
- $2.6 million
- Total capital raised
- $2.8 billion to $4.3 billion
- Market expansion
- 3400 instruments
- Estimated Revolution demand
- 2300 instruments
- Estimated Independence demand
Why it mattersThe smaller device opens new revenue from thousands of drug makers worldwide that the current system cannot reach.
